ACUTE MYELOID LEUKEMIA (AML)
TREATMENT AND TRIALS IN CHINA
Prepared by the CancerFax oncology navigation team. Updated regularly based on treatment access and clinical trial availability in China.
analyticsAt a Glance
- check_circleAML trials in China cover novel FLT3, IDH1/2, and BCL-2 targeted agents alongside transplant protocols
- check_circleVenclexta (venetoclax) combinations are available at major Chinese haematology centres
- check_circleCAR-T trials for AML targeting CD33, CD123, and CLL-1 are active in China
- check_circleCancerFax assists with eligibility review, medical summary translation, and hospital coordination
Understanding Acute Myeloid Leukemia
AML is a fast-growing cancer of the bone marrow in which abnormal myeloid blasts crowd out normal blood-forming cells, leading to anaemia, infections, and bleeding. Diagnosis is confirmed through bone marrow aspirate and biopsy, with cytogenetics, flow cytometry, and molecular testing to identify subtype and risk. Risk stratification today follows the European LeukemiaNet (ELN) framework, which classifies AML as favourable, intermediate, or adverse risk based on genetic and molecular features. Important findings include FLT3-ITD and FLT3-TKD mutations, NPM1, CEBPA, IDH1, IDH2, TP53, RUNX1, ASXL1, complex karyotype, and MDS-related changes. Risk classification directly influences whether transplant is recommended in first remission and which targeted agents may be used.
How AML Is Treated
Induction Therapy Most fit adults receive intensive induction chemotherapy, classically the โ7+3โ regimen of cytarabine and an anthracycline (daunorubicin or idarubicin). For FLT3-mutant AML, a FLT3 inhibitor such as midostaurin or quizartinib is added. CPX-351 (liposomal daunorubicin and cytarabine) is used for therapy-related and MDS-related AML. The goal is complete remission with measurable residual disease (MRD) testing to guide next steps. Consolidation Patients in remission usually receive consolidation, with high-dose cytarabine cycles for favourable-risk disease, or proceed to allogeneic stem cell transplant for intermediate- and adverse-risk AML, or for those with persistent MRD. The choice depends on age, fitness, donor availability, and risk profile. Lower-Intensity Regimens Older or unfit patients are increasingly treated with venetoclax combined with a hypomethylating agent (azacitidine or decitabine). This combination is now a standard of care for patients unable to tolerate intensive chemotherapy and is widely used in China alongside global practice. Hypomethylating agents alone, low-dose cytarabine, and IDH or FLT3 inhibitors as monotherapy are alternatives in selected cases. Targeted Therapy by Mutation
FLT3-mutant AML โ midostaurin (with induction), quizartinib
FLT3-mutant AML โ midostaurin (with induction), quizartinib (FLT3-ITD), and gilteritinib (relapsed/refractory).
IDH1-mutant AML โ ivosidenib, alone or with azacitidine in o
IDH1-mutant AML โ ivosidenib, alone or with azacitidine in older newly diagnosed patients.
IDH2-mutant AML โ enasidenib for relapsed or refractory dise
IDH2-mutant AML โ enasidenib for relapsed or refractory disease in selected patients.
Menin inhibitors โ emerging therapy for KMT2A (MLL)-rearrang
Menin inhibitors โ emerging therapy for KMT2A (MLL)-rearranged and NPM1-mutant AML, primarily in trials.
Acute promyelocytic leukemia (APL) โ a distinct AML subtype
Acute promyelocytic leukemia (APL) โ a distinct AML subtype usually treated with all-trans retinoic acid (ATRA) and arsenic trioxide, with very high cure rates. China was a pioneer in arsenic trioxide use for APL.
Allogeneic Stem Cell Transplant in China
Allogeneic transplant remains the most effective curative option for many AML patients, particularly those with intermediate- or adverse-risk disease, MRD-positive remission, or relapsed disease brought back into remission. Chinese centres have built one of the largest haploidentical (half-matched, usually parent-to-child or sibling) transplant programmes in the world, which is particularly valuable when a fully matched donor is not available. This is a meaningful access advantage for international patients without matched-donor options at home. Pre-transplant assessment includes donor selection (matched sibling, matched unrelated, haploidentical, or cord blood), conditioning regimen choice based on age and fitness, infection screening, and discussion of graft-versus-host disease (GVHD) prevention. Post-transplant care can extend over many months, and continuity planning is essential before international travel.
CAR-T, CAR-NK, and Novel Agent Trials in China
China has one of the most active early-phase cell therapy ecosystems for AML globally. While CAR-T therapy in AML remains investigational and more challenging than in lymphoid malignancies, multiple academic centres run trials of CAR-T cells and CAR-NK cells targeting CD33, CD123, CLL-1, CD7, and combination targets, often as a bridge to transplant rather than a standalone cure. Other trial categories include menin inhibitors for KMT2A-rearranged and NPM1-mutant AML, novel FLT3 and IDH inhibitor combinations, antibody-drug conjugates, bispecific antibodies, and combinations of venetoclax with novel agents. Eligibility for trials is strict and depends on disease status, prior therapies, organ function, and trial-specific criteria. Trial selection is never guaranteed.
How CancerFax Helps
CancerFax supports AML patients exploring care in China through a structured pathway:
Case review โ diagnosis, cytogenetics, molecular profile, pr
Case review โ diagnosis, cytogenetics, molecular profile, prior therapy, and current status are reviewed to clarify what options are realistic in China.
Treatment and trial mapping โ induction protocols, transplan
Treatment and trial mapping โ induction protocols, transplant programmes, targeted therapies, and CAR-T or novel agent trials are identified across major Chinese centres.
Hospital matching โ reports are shared with appropriate haem
Hospital matching โ reports are shared with appropriate haematology and transplant teams for structured feedback.
Donor and logistics planning โ guidance is provided on donor
Donor and logistics planning โ guidance is provided on donor options (including haploidentical), transplant timing, expected stay, and post-transplant follow-up.
Coordination and follow-up โ CancerFax supports admission, i
Coordination and follow-up โ CancerFax supports admission, interpreter needs, monitoring schedules, and continuity after returning home.
Where This May Be Available
AML care is delivered across major university and government cancer centres in cities such as Beijing, Tianjin, Shanghai, Suzhou, Guangzhou, and others. Some centres are particularly well known for high-volume haploidentical transplant programmes, while others lead in cell therapy and novel agent trials. The same patient may face different eligibility rules, admission timelines, and cost structures depending on the centre. CancerFax helps patients identify the most relevant pathway based on disease profile, prior treatment, transplant readiness, and trial fit โ rather than choosing a hospital by name alone.
Frequently Asked Questions
Answers to common questions from patients and families.
Is AML treatment in China comparable to the West?
Yes, in most respects. Major Chinese centres follow international guidelines for induction, consolidation, and transplant, and have access to many of the same targeted therapies. China leads globally in haploidentical transplant volume and in early-phase cell therapy trials, which can be meaningful advantages for patients without matched donors or after standard treatment failure. Quality varies by centre, so hospital selection matters.
Can I travel for AML treatment if I am newly diagnosed?
AML usually requires urgent treatment, often within days of diagnosis. For most newly diagnosed patients, induction therapy is started locally and international options are evaluated for consolidation, transplant, or relapse. In selected stable cases, early travel may be possible. CancerFax helps patients understand whether travel is realistic and how to coordinate without delaying critical care.
Is CAR-T therapy available for AML in China?
CAR-T and CAR-NK therapies for AML in China are mainly available through clinical trials at major academic centres, targeting molecules such as CD33, CD123, CLL-1, and CD7. Eligibility is strict and approval as standard treatment is limited. CAR-T in AML is often used as a bridge to transplant rather than a standalone cure. CancerFax helps patients evaluate trial fit and prepare reports for review.
How important is mutation testing in AML?
Very important. FLT3, NPM1, IDH1, IDH2, CEBPA, TP53, KMT2A, and other mutations directly affect prognosis, transplant decisions, and the choice of targeted therapy. A complete cytogenetic and molecular profile (ideally a myeloid NGS panel) should be available before any major treatment decision. CancerFax helps patients ensure the right tests are done and interpreted in context before treatment planning.
What if I do not have a matched donor for transplant?
Chinese centres run some of the largest haploidentical (half-matched) transplant programmes in the world, allowing many patients to proceed to transplant using a parent, child, or sibling as donor when a fully matched donor is unavailable. Cord blood transplant is another option in selected cases. Donor selection depends on patient age, disease risk, and available family members. CancerFax helps families assess donor options early.
Can older or unfit patients be treated effectively?
Yes. Lower-intensity regimens such as venetoclax combined with azacitidine or decitabine have meaningfully improved outcomes for older or unfit AML patients and are widely used in China. IDH and FLT3 inhibitors as monotherapy or in combination are also options when relevant mutations are present. The right approach balances efficacy, tolerability, and patient goals, and should be decided by the treating team.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Help Understanding Your Options?
If you or a family member has been diagnosed with AML โ newly diagnosed, in remission considering transplant, or with relapsed disease โ CancerFax can help organise the medical records, review cytogenetic and molecular reports, and connect the case with appropriate Chinese haematology, transplant, and clinical trial teams. Share your reports to receive structured guidance before making travel or t
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.